* Advanced Tissue Sciences Inc., of La Jolla, Calif., is discontinuingsales of its Skin2 product line to focus all resources on therapeutics.Skin2 is a living human skin tissue that has been used mainly for invitro testing of new materials and compounds.
* Anergen Inc., of Redwood City, Calif., said underwriters of itsrecent follow-on offering exercised an overallotment option on168,000 shares, raising the gross proceeds to about $11 million. Thecompany initially sold 3.5 million shares at $3 each. It now has 18.7million shares outstanding.
* Aprogenex Inc., of Houston, is collaborating with AmCell Corp., ofSunnyvale, Calif., which will use Aprogenex's DNA probes insystems it is developing to screen maternal blood for circulating fetalcells. The goal is to identify prenatal genetic disorders.
* Boston Life Sciences Inc., of Boston, said its anti-angiogenic factorappeared to significantly inhibit angiogenesis in animal models. Thefactor was used for six days after fibroblast growth factor wasimplanted into the eyes of mice to stimulate blood vessel growth inthe cornea. The company plans to move into animal tumor models.
* Chiron Corp., of Emeryville, Calif., formally changed the name ofits 10-year-old vaccine business from Chiron Biocine to ChironVaccines. Chiron Vaccines' primary operations are conducted inEmeryville; Siena, Italy; and Marburg, Germany.
* Gensia Inc., of San Diego, said its subsidiary received approval ofan abbreviated new drug application for fluphenazine decanoateinjection USP, a drug for management of schizophrenia.
* NeoPharm Inc., of Lake Forest, Ill., said its stock split wascompleted and both the stock (NASDAQ:NPRM) and warrants(NASDAQ:NPRMW) began trading Monday at the post-split price.
* T Cell Sciences Inc., of Needham, Mass., was awarded a $100,000Small Business Innovation Research grant from the NationalInstitutes of Health to develop a transgenic rat atherosclerosis model.It will contribute to the company's program to develop a vaccinebased on cholesteryl ester transfer protein.
* Vical Inc., of San Diego, is collaborating with Ronald Levy, aprofessor at Stanford University Medical Center in Palo Alto, Calif.,to proceed toward clinical trials with a potential DNA protectivevaccine against B cell lymphoma. The vaccine would use Vical'snaked DNA technology to deliver a gene that may cause muscle cellsto produce a substance, idiotypic determinant, unique to the targettumor cells.
* Virologix Corp., of New York, said data presented in Baltimore atthe annual meeting of Tumor Cell Biology showed its vaccinecandidate for T cell leukemia virus type II elicited high antibodytiters and protection against viral infection in rabbits. The subunitvaccine based on a viral glycoprotein is expected to go into humanstudies in 1997.
(c) 1997 American Health Consultants. All rights reserved.